Compare Medpace Holdings Inc (MEDP) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Palo Alto Networks Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Palo Alto Networks Inc trades at $418.78 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 19.7× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 3,886,927). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Palo Alto Networks Inc for 82 Days on average.
| MEDP | PANW | |
|---|---|---|
Market Cap | $16.82B | $331.76B |
Volume | 223,093 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $630.19 | $419.91 |
52-Week Low | $393.42 | $141.67 |
Typical Hold Time | 14 Days | 82 Days |
Enterprise Value | $16.44B | $331.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Palo Alto Networks (PANW) trades at $398.50, down 1.7% on the day but near its 52-week high, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $5.5B in 2022 to $9.2B in 2025, though net income margin compressed to 2.67% in 2026 from 12.29% in 2025. Positive sentiment is driven by AI cybersecurity demand and platformization strategy.
The outlook remains favorable given strong analyst support (72% buy ratings) and a consensus price target of $398.70, but high valuation multiples (P/E 1,013.93, P/S 26.99) and rising costs pose risks. Earnings execution and AI-driven security adoption are key catalysts, while premium valuation and competitive pressures require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
